Trials / Completed
CompletedNCT04762407
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903
An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HCP1903 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HGP1910 | Take it once per period. |
| DRUG | HGP1909 | Take it once per period. |
| DRUG | HCP1903 | Take it once per period. |
Timeline
- Start date
- 2020-11-20
- Primary completion
- 2021-02-24
- Completion
- 2021-02-24
- First posted
- 2021-02-21
- Last updated
- 2022-07-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04762407. Inclusion in this directory is not an endorsement.